Gene Therapy for Neurodegenerative Diseases Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Major companies in the Gene Therapy for Neurodegenerative Diseases Market include, Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics, Krystal Biotech, Avexis.
Global Snapshot of Gene Therapy for Neurodegenerative Diseases Market:
The 2025 Gene Therapy for Neurodegenerative Diseases Market Report offers an exhaustive analysis encompassing the components, patterns, flows, and sizes influencing market development.Employing both primary and secondary data sources, this exploration of Gene Therapy for Neurodegenerative Diseases combines present and past market values to project potential market trajectories from 2025 to 2032. It encompasses a comprehensive examination of diverse industry parameters, spanning government policies, market environments, competitive landscapes, historical data, current market trends, technological innovations, upcoming technologies, and progress within related industries.Furthermore, the report delves into the intricate dynamics of the value chain and supply chain, elucidating the augmentation of value at each stage in the product lifecycle.The study encapsulates market dynamics such as drivers, restraints/challenges, trends, and their ripple effect on the market.
This Market Research Report not only delivers an all-encompassing analysis of the Global Gene Therapy for Neurodegenerative Diseases Market but also accentuates key trends pertaining to product segmentation, company formation, revenue, market share, latest developments, and M&A activities.The report meticulously examines the strategies employed by leading global companies, concentrating on portfolios and capabilities, market entry strategies, market positions, and geographic footprints.This deep dive aims to illuminate the distinctive positioning of these firms in an ever-accelerating Global Gene Therapy for Neurodegenerative Diseases Market.
In the categorization of the Global Gene Therapy for Neurodegenerative Diseases Market, there are distinct segments based on type and application:
By Type Segmentation:
Gene Replacement Therapy
Gene Silencing Therapy
Gene Editing Therapy
Enzyme Replacement Therapy
By Application Segmentation:
Hospitals and Clinics
Research Institutions
Biotechnology Companies
Others
This delineation facilitates a comprehensive understanding of the market, allowing for a focused examination of each type and its applications in various fields.
Regional Breakdown of the Global Gene Therapy for Neurodegenerative Diseases Market:
North America: U.S., Canada, Mexico
Eastern Europe: Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe
Western Europe: Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe
Asia-Pacific: China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC
South America: Brazil, Argentina, Rest of SA
Middle East & Africa: Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa
Understanding Competitive Dynamics in Gene Therapy for Neurodegenerative Diseases Market:
The evaluation of the Competitive Landscape within the Gene Therapy for Neurodegenerative Diseases Market involves a comprehensive analysis of the strengths and weaknesses, market investments, market share, market sales volume, and market trends exhibited by key players in the industry.This study encompasses all primary, secondary, and tertiary level competitors. The data for this analysis is derived from both primary and secondary research methodologies. The report provides a detailed examination of drivers, constraints, and opportunities for new entrants aiming to establish a presence in the market.
Key Questions answered in the Gene Therapy for Neurodegenerative Diseases Market Research Report:
1. What is the projected size of the market in 2032, and the anticipated Compound Annual Growth Rate (CAGR) during the forecast period?
2. Which major companies are prominent players in the Market?
3. What insights are provided into the components, patterns, and flows influencing the development, considering both primary and secondary data sources?
4. How does the market analysis incorporate government policies, market environments, and competitive landscapes to project potential market trajectories from 2025 to 2032. ?
5. In what ways does the report delve into the dynamics of the value chain and supply chain, elucidating the augmentation of value at each stage in the product lifecycle within the market?
6. What are the key market dynamics, including drivers, restraints/challenges, and trends, and how do they impact?
7. How does the Market Research Report highlight trends related to product segmentation, company formation, revenue, market share, latest developments, and M&A activities?
8. What strategies are leading global companies employing in the market, focusing on portfolios, capabilities, market entry, positions, and geographic footprints?
9. What are the distinct segments based on type and application in the market, and how does this categorization contribute to a comprehensive understanding of the market dynamics?
10. What insights are provided into the regional breakdown of the market, particularly in North America, Eastern Europe, Western Europe, Asia-Pacific, South America, and the Middle East & Africa?
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Gene Therapy for Neurodegenerative Diseases Market by Type
5.1 Gene Therapy for Neurodegenerative Diseases Market Overview Snapshot and Growth Engine
5.2 Gene Therapy for Neurodegenerative Diseases Market Overview
5.3 Gene Replacement Therapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Gene Replacement Therapy: Geographic Segmentation
5.4 Gene Silencing Therapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Gene Silencing Therapy: Geographic Segmentation
5.5 Gene Editing Therapy
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Gene Editing Therapy: Geographic Segmentation
5.6 Enzyme Replacement Therapy
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Enzyme Replacement Therapy: Geographic Segmentation
Chapter 6: Gene Therapy for Neurodegenerative Diseases Market by Application
6.1 Gene Therapy for Neurodegenerative Diseases Market Overview Snapshot and Growth Engine
6.2 Gene Therapy for Neurodegenerative Diseases Market Overview
6.3 Hospitals and Clinics
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals and Clinics: Geographic Segmentation
6.4 Research Institutions
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Research Institutions: Geographic Segmentation
6.5 Biotechnology Companies
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Biotechnology Companies: Geographic Segmentation
6.6 Others
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Gene Therapy for Neurodegenerative Diseases Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Gene Therapy for Neurodegenerative Diseases Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Gene Therapy for Neurodegenerative Diseases Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 VOYAGER THERAPEUTICS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 UNIQURE N.V.
7.4 AXOVANT GENE THERAPIES
7.5 NOVARTIS AG
7.6 AMICUS THERAPEUTICS
7.7 REGENXBIO INC.
7.8 SAREPTA THERAPEUTICS
7.9 GENSIGHT BIOLOGICS
7.10 KRYSTAL BIOTECH
7.11 AVEXIS
Chapter 8: Global Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Gene Replacement Therapy
8.2.2 Gene Silencing Therapy
8.2.3 Gene Editing Therapy
8.2.4 Enzyme Replacement Therapy
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospitals and Clinics
8.3.2 Research Institutions
8.3.3 Biotechnology Companies
8.3.4 Others
Chapter 9: North America Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Gene Replacement Therapy
9.4.2 Gene Silencing Therapy
9.4.3 Gene Editing Therapy
9.4.4 Enzyme Replacement Therapy
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospitals and Clinics
9.5.2 Research Institutions
9.5.3 Biotechnology Companies
9.5.4 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Gene Replacement Therapy
10.4.2 Gene Silencing Therapy
10.4.3 Gene Editing Therapy
10.4.4 Enzyme Replacement Therapy
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospitals and Clinics
10.5.2 Research Institutions
10.5.3 Biotechnology Companies
10.5.4 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Gene Replacement Therapy
11.4.2 Gene Silencing Therapy
11.4.3 Gene Editing Therapy
11.4.4 Enzyme Replacement Therapy
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospitals and Clinics
11.5.2 Research Institutions
11.5.3 Biotechnology Companies
11.5.4 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Gene Replacement Therapy
12.4.2 Gene Silencing Therapy
12.4.3 Gene Editing Therapy
12.4.4 Enzyme Replacement Therapy
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospitals and Clinics
12.5.2 Research Institutions
12.5.3 Biotechnology Companies
12.5.4 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Gene Replacement Therapy
13.4.2 Gene Silencing Therapy
13.4.3 Gene Editing Therapy
13.4.4 Enzyme Replacement Therapy
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospitals and Clinics
13.5.2 Research Institutions
13.5.3 Biotechnology Companies
13.5.4 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Gene Therapy for Neurodegenerative Diseases Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Gene Replacement Therapy
14.4.2 Gene Silencing Therapy
14.4.3 Gene Editing Therapy
14.4.4 Enzyme Replacement Therapy
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospitals and Clinics
14.5.2 Research Institutions
14.5.3 Biotechnology Companies
14.5.4 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Gene Therapy for Neurodegenerative Diseases Scope:
Report Data
|
Gene Therapy for Neurodegenerative Diseases Market
|
Gene Therapy for Neurodegenerative Diseases Market Size in 2025
|
USD XX million
|
Gene Therapy for Neurodegenerative Diseases CAGR 2025 - 2032
|
XX%
|
Gene Therapy for Neurodegenerative Diseases Base Year
|
2024
|
Gene Therapy for Neurodegenerative Diseases Forecast Data
|
2025 - 2032
|
Segments Covered
|
By Type, By Application, And by Regions
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
Key Companies Profiled
|
Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics, Krystal Biotech, Avexis.
|
Key Segments
|
By Type
Gene Replacement Therapy Gene Silencing Therapy Gene Editing Therapy Enzyme Replacement Therapy
By Applications
Hospitals and Clinics Research Institutions Biotechnology Companies Others
|